Table 10.6i
Immunosuppression Use for Antirejection Treatment from Transplant to One Year Following Transplantation, 1995 to 2004
Recipients with Intestine Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	46	45	68	70	73	82	112	107	116	152
Tx with Antirejection Treatments	32	28	46	24	34	45	41	48	65	58
Antibodies										
Any in Category	40.6%	25.0%	17.4%	20.8%	47.1%	48.9%	36.6%	31.3%	38.5%	44.8%
ALG	9.4%	3.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	0.0%	3.6%	0.0%	4.2%	0.0%	0.0%	2.4%	2.1%	0.0%	3.4%
OKT3	34.4%	17.9%	17.4%	12.5%	44.1%	31.1%	34.1%	29.2%	27.7%	34.5%
Thymoglobulin	0.0%	0.0%	0.0%	0.0%	11.8%	17.8%	7.3%	6.3%	3.1%	13.8%
Zenapax	0.0%	0.0%	0.0%	4.2%	5.9%	6.7%	0.0%	2.1%	0.0%	0.0%
Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	6.7%	0.0%	0.0%	0.0%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	8.3%	15.4%	6.9%
Corticosteroids										
Any in Category	90.6%	92.9%	93.5%	91.7%	85.3%	75.6%	80.5%	95.8%	92.3%	93.1%
Steroids	90.6%	92.9%	93.5%	91.7%	85.3%	75.6%	80.5%	95.8%	92.3%	93.1%
Antimetabolites										
Any in Category	0.0%	3.6%	0.0%	0.0%	0.0%	0.0%	2.4%	0.0%	0.0%	0.0%
Cytoxan	0.0%	3.6%	0.0%	0.0%	0.0%	0.0%	2.4%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.